Early results from a Phase I clinical trial of AT101, a new CAR T cell therapy that uses a distinct binding mechanism to target CD19, show a 100 percent complete response (CR) rate at the higher dose levels studied in the trial, according to researchers from the University of Pennsylvania Perelman School of Medicine and Penn Medicine’s Abramson Cancer Center.
Eckert & Ziegler Signs Strategically Important Agreement for the Supply of Lutetium-177 with POINT Biopharma – Biotech Investments
Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Contract Eckert & Ziegler Signs Strategically Important Agreement for the Supply of Lutetium-177 with POINT
September 27, 2023